Advanced therapies designed to treat common conditions in England will not receive additional funding, according to a former senior figure at the National Institute for Health and Care Excellence (NICE).
Health technology assessment agencies are prepared to pay more than usual for advanced therapies addressing rare or severe diseases. However, a former senior figure at England’s NICE has stated that advanced therapies targeting common conditions would not be eligible for such modifiers.
NICE bases its payment modifiers on the intended patient population, not the therapy itself (Shutterstock)
